ArticleJournal of clinical microbiology2024
Trends in the activity of mold-active azole agents against
Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease.Antimicrobial agents and chemotherapy · 2026Trial
- Ten-Year Voriconazole Susceptibility Trends Among 1482 ClinicalJournal of fungi (Basel, Switzerland) · 2026Article
- Activity of Isavuconazole and Comparator Agents Against Pediatric Isolates From Invasive Fungal Infections.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Misleading presentation of tuberculosis in a child with CGD revealing invasive aspergillosis: A molecularly confirmed case.IDCases · 2026Article
- Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- Azole Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction inJournal of clinical microbiology · 2025Article
- Antifungal Minimal Inhibitory Concentrations of Mold Isolates from Patients with Cancer; Single-Center Experience, 2018-2023.Journal of fungi (Basel, Switzerland) · 2025Article
- Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Use of voriconazole to predict susceptibility and resistance to isavuconazole forJournal of clinical microbiology · 2025Article
- Comprehensive Review of Environmental Surveillance for Azole-ResistantJournal of fungi (Basel, Switzerland) · 2025Review
- An approach to making life sciences FAIR-FAIR-DS as a tool for Aspergillus fumigatus.Database : the journal of biological databases and curation · 2025Article
- Exploring the role and mechanisms of theMycology · 2025Article
- Epidemiology and Antifungal Susceptibilities of Clinically IsolatedInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azole resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.